Results showed one complete response to therapy and 17 partial responses in patients.
Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus pemetrexed may be a promising frontline option for older patients with metastatic nonsquamous NSCLC and a PD-L1 tumor proportion score (TPS) below 50%.1
After a median follow-up of 15.4 months (range, 0.3-34.5), data showed an objective response rate (ORR) of 36.7% (95% CI, 23.4%-51.7%; P = .005), which included 1 complete response (CR) and 17 partial responses (PRs). Additionally, the disease control rate (DCR) was 65.3% (95% CI, 50.4%-78.3%).
Among those with a response, the median duration of response (DOR) was 13.3 months (95% CI, 6.1-22.8), with 61.1% experiencing a sustained response for 12 months or longer….